Cagrilintide-semaglutide combination achieves 12.4 percentage point greater weight loss than placebo in type 2 diabetes

Type 2 diabetes (T2D) is a progressive metabolic disorder characterized by insulin resistance and impaired insulin secretion, often leading to hyperglycemia and significant cardiovascular risks. Current pharmacotherapies, while effective in managing blood glucose, frequently fall short in addressing the associated obesity and achieving sustained, substantial weight loss, which is crucial for long-term disease remission and complication prevention. The combination of GLP-1 receptor agonists (like semaglutide) and amylin receptor agonists (like cagrilintide) offers a synergistic approach, targeting distinct but complementary pathways involved in glucose homeostasis, appetite regulation, and gastric emptying, thus presenting a promising strategy to overcome the limitations of monotherapy.

The REIMAGINE 2 study was a double-blind, randomized, controlled, phase 3 clinical trial investigating the efficacy and safety of cagrilintide-semaglutide in individuals with type 2 diabetes whose condition was inadequately controlled by existing treatments. Participants were randomized to receive once-weekly subcutaneous injections of cagrilintide-semaglutide (2.4 mg each), semaglutide alone, cagrilintide alone, or placebo. The primary endpoint assessed was the estimated mean relative change in bodyweight from baseline to week 40. Secondary endpoints likely included various glycemic parameters and safety profiles, though specific details are not provided in this abstract snippet.

The combination of cagrilintide-semaglutide demonstrated superior efficacy compared to placebo in reducing bodyweight in patients with type 2 diabetes.

Participants receiving cagrilintide-semaglutide (2.4 mg each) achieved an estimated mean relative change in bodyweight of -13.8% (SE 1.0) from baseline to week 40. In stark contrast, the placebo group experienced only a -1.4% (SE 0.7) reduction in bodyweight over the same period. This resulted in a statistically significant estimated treatment difference of -12.4 percentage points (95% CI -14.7 to -10.0) in favor of the combination therapy. While specific glycemic control metrics are not detailed in this abstract, the overall context of the study as a "new option for patients with type 2 diabetes" implies significant improvements in these areas as well, alongside the substantial weight loss. The study also aimed to assess safety, suggesting tolerability data was collected.